Wound Antiseptic Study With Hypochlorous Acid & Iodopovidone

Comparative Study of Two Antiseptics Solutions for the Prevention of Surgical Site Infection

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00692757

Acronym

WASH

Enrollment

432

Registered

2008-06-06

Start date

2008-07-31

Completion date

2009-03-31

Last updated

2008-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection

Keywords

Hypochlorous Acid, Colony forming units, surgical site infection, nosocomial infection, bacterial bioburden, wound healing

Brief summary

The purpose of this study is to determine whether hypochlorous acid is an effective antiseptic agent to prevent surgical site infection.

Detailed description

A topical antimicrobial that decrease the bacterial bioburden of surgical wounds without impairing the wound's ability to heal is a need. A stabilized form of hypochlorous acid has been demonstrated in vitro and in animal studies to possess properties that could fulfill these criteria but it is imperative to assess its efficacy and safety in humans. To assess hypochlorous acid efficacy and safety, it was designed a clinical controlled randomized trial to compare hypochlorous acid to iodopovidone, the gold standard, in preoperative scrub of surgical area.

Interventions

DRUGHypochlorous acid

Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray

DRUGIodopovidone

Iodopovidone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients over 18 years old, who are going to be operated * Classification of surgical wounds according to the National Research Council as class I or II * Risk index classification of the American Society of Anaesthesiology (ASA) as ASA 1 or 2

Exclusion criteria

* Patients requiring mesh or prosthesis or orthesis

Design outcomes

Primary

Measure	Time frame
Surgical site infection rates	until one month (weekly)

Secondary

Measure	Time frame
Decreasing Colony Forming Unit count (CFU/mL) after using the skin topic antiseptic in surgical site	one week

Countries

Colombia

Contacts

Primary ContactJuliana Buitrago, Master

julianabuitrago@yahoo.com313-649-0439

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026